Increased Antitumor Effect of Immunoconjugates and Tumor Necrosis Factor in Vivo

Cancer Research

Volumn 48, Issue 13, 1988, Pages 3607-3612

  Smyth, Mark J ^a   Pietersz, Geoffrey A ^a   McKenzie, Ian F ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; N ACETYLMELPHALAN; RADIOISOTOPE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CELL CULTURE; MOUSE; NONHUMAN; THYMOMA;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; IMMUNOTHERAPY; IMMUNOTOXINS; MICE; RECOMBINANT PROTEINS; THYMOMA; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR;

EID: 0023749661     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Smyth, M. J., Pietersz, G. A., and McKenzie, I. F. C. Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. Cancer Res., 47:62-69, 1987.
2. Rowland, G. F., Corvalan, J. R. F., Axton, C. A., Gore, V. A., Marsden, C. H., Smith, W., and Simmonds, R. G. Suppression of growth of a human colorectal tumor in nude mice by vindesine-monodonal anti-CEA conjugates. In: H. Peeters (ed.), Protides of the Biological Fluids, Vol. 31, pp. 783–786. Oxford: Pergamon Press, 1983.
3. Thorpe, P. E., Detre, S. I., Foxwell, B. M. J., Brown, A. N. F., Skilleter, D. N., Wilson, G., Forrester, J. A., and Stirpe, F. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur. J. Biochem., 147:197-206,1985.
4. Larson, S. M. Radiolabeled monoclonal antitumor antibodies in diagnosis and therapy. J. Nucl. Med., 26:538-545,1985.
5. Greiner, J. W., Guadagni, F., Noguchi, P., Pestka, S., Colcher D., Fisher, P., and Schlom, J. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science (Wash. DC), 235: 895–898, 1987.
6. Weil-Hillman, G., Uckun, F. M., Manske, J. M., and Vallera, D. A. Combined immunocbemotherapy of human solid tumors in nude mice. Cancer Res., 47:579-585,1987.
7. Smyth, M. J., Pietersz, G. A., and McKenzie, L F. C. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. J. Natl Cancer Inst, 79:1367-1373,1987.
8. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72:3666-3670,1975.
9. Vilcek J., Palombella, V. J., Henriksen-Destefano, D., Swenson, C., Fein-man, R., Hirai, M., and Tsujimoto M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J. Exp. Med., 163:632-643,1986.
10. Sugarman, B. J., Aggarwal, B. B., Hass, P. E., Figari, I. S., Palladino, M. A., and Shepard, H. M. Recombinant human tumor necrosis factor-a: effects on proliferation of normal and transformed cells in vitro. Science (Wash. DC), 230:943-945,1985.
11. Rubin, B. Y., Anderson, S. L., Sullivan, S. A., Williamson, B. D., Carswell, E. A., and Old, L. J. High affinity binding of 129I-labeled human tumor necrosis factor (LulcII) to specific cell surface receptors. J. Exp. Med., 162: 1099-1104,1985.
12. Baglioni, C., McCandless, S., Taverner, J., and Fiers, W. Binding of human tumor necrosis factor to high affinity receptors on Hela cells. J. Biol. Chem., 260:13395-13397,1985.
13. Tsujimoto M., Yip, Y. K., and Vilcek, J. Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc. Natl. Acad. Sci. USA, 82:7626-7630,1985.
14. MacPherson, G. G., and North, R. J. Endotoxin-mediated necrosis and regression of established tumors in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer Im-munol. Immunother, 21:209-216,1986.
15. Hogarth, P. M., Edwards, J., McKenzie, I. F. C., Goding, J. W., and Liew, F. Y. Monoclonal antibodies to murine Ly-2.1 cell surface antigen. Immunology, 46:135-144,1982.
16. Hass, P. E., Hotchkiss, A., Mohler, M., and Aggarwal, B. B. Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts. J. Biol. Chem., 260:12214-12218,1985.
17. Beutler B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y. C., Mathison, J., Ulevitch, R., and Cerami, A. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature (Lond.), 316:552-554,1985.
18. Beouckaert, P. G. G., Leroux-Roels, G. G., Guisez, Y., Taverner, J. and Fiers, W. In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with murine IFN-7, on a syngeneic murine melanoma. Int. J. Cancer, 38:763-769,1986.
19. Regenass, U., Muller, M., Curschellas, E., and Matter, A. Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int. J. Cancer, 39:266-273,1987.
20. Fransen, L., Ruysschaert, M. R., Van der Heyden, J., and Fiers, W. Recombinant tumor necrosis factor species-specificity for a variety of human and murine transformed cell lines. Cell Immunol, 100:260-267,1986.
21. Beutler, B., and Cerami, A. Cachectin: more than a tumor necrosis factor. N. Engl. J. Med., 316:379-385,1987.
22. Asher, A., Mule J. J., Reichert, C. M., Shiloni, E., and Rosenberg, S. A. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol., 738:963-974,1987.
23. Frankel, A. E., Houston, M. D., Issell, B. F., and Fathman, G. Prospects for immunotoxin therapy in cancer. Annu. Rev. Med., 37:125-142,1986.
24. Epenetos, A. A., Snook, D., Durbin, H., Johnson, P. M., and Taylor-Papadimitriou, J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res., 46:3183-3191,1986.
25. Nawroth, P. P., and Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 163:740-745,1986.
26. Pober, J. S., Bevilacqua, M. P., Mendrick D. L., Lapierre, L. A., Fiers, W., and Gimbrone, M. A., Jr. Two distinct monokines, interleukin-1 and tumor necrosis factor-a, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J. Immunol., 136:1680-1687,1986.
27. Nawroth, P. P., Bank, I., Handley, D., Cassimeris, J., Chess, L., and Stern, D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce the release of interleukin-1. J. Exp. Med., 163:1363-1375,1986.
28. Stolphen, A. H., Guinan, E. C., Fiers, W., and Pober, J. S. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am. J. Pathol., 123:16-24,1986.
29. Sato, N., Goto, T., Haranaka, K., Satomi, N., Nariuchi, H., Mano-Hirano, Y., and Saswaski, Y. Actions of tumor necrosis factor on cultured vascular endothelial cells morphologic modulation, growth inhibition, and cytotoxicity. J. Natl. Cancer Inst, 76:1113-1121,1986.
30. Urban, J. L., Shepard, H. M., Rothstein, J. L. Sugarman, B. J., and Schreiber, H. Tumour necrosis factor a potent effector molecule for tumour cell killing by activated macrophages. Proc. Natl. Acad. Sci. USA, 83:5233-5237,1986.
31. Philip, R., and Epstein, L. B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself 7-interferon, and interleukin-1. Nature (Lond.), 323:86-89,1986.
32. Creasy, A. A., Doyle, L. V., Reynolds, M. T., Jung, T., Lin, L. S., and Vitt, C. R. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res., 47: 145–149, 1987.
33. Kettelhut, I. C., Fiers, W., and Goldberg, A. L. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc. Natl Acad. Sci. USA, 84:4273-4277,1987.